Medirom Subsidiary Completes Series A Financing
Ticker: MRM · Form: 6-K · Filed: Dec 13, 2024 · CIK: 1819704
Sentiment: neutral
Topics: financing, subsidiary, press-release
TL;DR
Medirom's subsidiary MEDIROM MOTHER Labs just closed a Series A funding round.
AI Summary
Medirom Healthcare Technologies Inc. announced on December 13, 2024, that its subsidiary, MEDIROM MOTHER Labs Inc., has completed a Series A equity financing round. The press release detailing this financing is attached as Exhibit 99.1 to this Form 6-K filing.
Why It Matters
This financing round indicates investor confidence in the subsidiary's growth potential and provides capital for future development and expansion.
Risk Assessment
Risk Level: low — The filing is an informational report about a subsidiary's financing and does not contain significant new financial risks for the parent company.
Key Players & Entities
- Medirom Healthcare Technologies Inc. (company) — Registrant
- MEDIROM MOTHER Labs Inc. (company) — Subsidiary
- December 13, 2024 (date) — Announcement Date
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is being filed to report the issuance of a press release by Medirom Healthcare Technologies Inc. concerning the Series A equity financing round of its subsidiary, MEDIROM MOTHER Labs Inc.
When was the press release regarding the financing issued?
The press release was issued on December 13, 2024.
Which subsidiary of Medirom Healthcare Technologies Inc. completed the Series A financing?
MEDIROM MOTHER Labs Inc., a subsidiary of Medirom Healthcare Technologies Inc., completed the Series A equity financing round.
Is the press release considered 'filed' for SEC purposes?
No, the press release furnished as Exhibit 99.1 is not deemed to be 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.
What is the principal executive office address of Medirom Healthcare Technologies Inc.?
The principal executive office is located at 2-3-1 Daiba, Minato-ku, Tokyo 135-0091, Japan.
Filing Stats: 275 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-12-13 16:05:14
Filing Documents
- tmb-20241213x6k.htm (6-K) — 13KB
- tmb-20241213xex99d1.htm (EX-99.1) — 24KB
- tmb-20241213xex99d1001.jpg (GRAPHIC) — 6KB
- tmb-20241213xex99d1003.jpg (GRAPHIC) — 8KB
- tmb-20241213xex99d1004.jpg (GRAPHIC) — 8KB
- 0001558370-24-016231.txt ( ) — 69KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MEDIROM HEALTHCARE TECHNOLOGIES INC. Date: December 13, 2024 By: /s/ Fumitoshi Fujiwara Name: Fumitoshi Fujiwara Title: Chief Financial Officer